Who Paid My Doc
Mehul Desai
Pain Medicine Washington, DC Medical Doctor
NPI 1114045341 CMS profile 322938
2141 K St Nw, Suite 600, Washington, DC 20037
General payments
$339,070
Research payments
$7,061
Ownership & investment interest
$101,820
Research they led as principal investigator
$1,038,289
Through program year 2025, Mehul Desai of Washington, DC is reported in the CMS Open Payments database as having received $339,070 across 737 general payments and $7,061 in research payments paid to them. Separately, studies naming them as principal investigator received $1,038,289 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $101,820 across 6 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
16 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $43,403 | 82 | |
| 2024 | General | $47,270 | 78 | |
| 2023 | General | $96,080 | 145 | |
| 2023 | Research | $1,161 | 2 | |
| 2022 | General | $78,564 | 93 | |
| 2022 | Research | $4,700 | 6 | |
| 2021 | General | $38,675 | 130 | |
| 2021 | Research | $1,200 | 4 | |
| 2020 | General | $12,677 | 78 | |
| 2019 | General | $22,400 | 131 | |
| 2025 | Ownership | $18,210 | 1 | |
| 2024 | Ownership | $18,210 | 1 | |
| 2023 | Ownership | $18,210 | 1 | |
| 2022 | Ownership | $18,210 | 1 | |
| 2021 | Ownership | $18,210 | 1 | |
| 2020 | Ownership | $10,770 | 1 |
Beside peers
- Mehul Desai
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Mehul Desai were reported at $43,403. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.
Show as a table
| Year | Mehul Desai | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $22,400 | $409 | $115–$1,311 | $163 |
| 2020 | $12,677 | $214 | $66–$666 | $114 |
| 2021 | $38,675 | $299 | $84–$899 | $132 |
| 2022 | $78,564 | $335 | $103–$1,149 | $149 |
| 2023 | $96,080 | $376 | $114–$1,228 | $160 |
| 2024 | $47,270 | $387 | $115–$1,173 | $164 |
| 2025 | $43,403 | $402 | $130–$1,173 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
175
Drug cost
$2,511
Branded share of claims
17.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Tizanidine Hcl | Generic | 62 | $814 | |
| Oxycodone Hcl | Generic | 21 | $518 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 19 | $388 | |
| Baclofen | Generic | 18 | $276 | |
| Cephalexin | Generic | 13 | $203 | |
| Gabapentin | Generic | 20 | $119 | |
| Hydromorphone Hcl | Generic | 11 | $101 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 11 | $91 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 70 billing codesPaid by Medicare
$351,045
Medicare patients
569
Services billed
2,642
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 70% | |
| Depression | 30% | |
| Ischemic heart disease | 27% | |
| Osteoporosis | 26% | |
| Diabetes | 23% | |
| Chronic kidney disease | 19% | |
| Cancer | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
749 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Pain Medicine in District of Columbia
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in District of Columbia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.